Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 151 participants.

Also called NCT02585674

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 151 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02585674
  • EudraCT 2014-004533-13
Other papers using this trial's data
  • A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study Diabetes care, 2018-08 DOI, PubMed 29895556 PubMed links an erratum for this paper. Erratum: PMID 31227584

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Germany, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02585674. Randomized; no masking; primary purpose treatment. Start 2015-12 (registry gives no type); primary completion 2016-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo
Acronym
AUTOMATIX
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Insulin glargine (U300)
Intervention (Device)
MyStar DoseCoach
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02585674
Content hash
21d2b78df19097255953d50cb6bde119a056a98eb4ad7f6533c27542340f7d0e